SOP1812( QN-302), is a tetra-substituted naphthalene diimide (ND) derivative and selective inhibitor of G-quadruplex (G4) transcription. It shows great affinity to hTERT G4 and HuTel21 G4 with KD values of 4.9 and 28.4 nM, respectively. It binds to G-quadruplex DNA in cancer gene promoters region and shows strong anti-proliferative and anti-tumor activity in pancreatic cancer […]

SOP1812( QN-302), is a tetra-substituted naphthalene diimide (ND) derivative and selective inhibitor of G-quadruplex (G4) transcription. It shows great affinity to hTERT G4 and HuTel21 G4 with KD values of 4.9 and 28.4 nM, respectively. It binds to G-quadruplex DNA in cancer gene promoters region and shows strong anti-proliferative and anti-tumor activity in pancreatic cancer […]

Atogepant(MK-8031, AGN-241689) is a potent, selective, orally available antagonist of the calcitonin gene-related peptide (CGRP) receptor, with ki of 0.026 nM for human CGRP receptor. It is used for the preventive treatment episodic migraine.

Atogepant(MK-8031, AGN-241689) is a potent, selective, orally available antagonist of the calcitonin gene-related peptide (CGRP) receptor, with ki of 0.026 nM for human CGRP receptor. It is used for the preventive treatment episodic migraine.

Atogepant(MK-8031, AGN-241689) is a potent, selective, orally available antagonist of the calcitonin gene-related peptide (CGRP) receptor, with ki of 0.026 nM for human CGRP receptor. It is used for the preventive treatment episodic migraine.

Atogepant(MK-8031, AGN-241689) is a potent, selective, orally available antagonist of the calcitonin gene-related peptide (CGRP) receptor, with ki of 0.026 nM for human CGRP receptor. It is used for the preventive treatment episodic migraine.

Irpagratinib (ABSK011) is a potent inhibitor of FGFR4 with an IC50 of < 10 nM in biochemical assays. It effectively suppresses FGFR4 auto-phosphorylation and disrupts downstream signal transduction. It also strongly inhibits tumor growth and induces regression in subcutaneous xenograft models.

Irpagratinib (ABSK011) is a potent inhibitor of FGFR4 with an IC50 of < 10 nM in biochemical assays. It effectively suppresses FGFR4 auto-phosphorylation and disrupts downstream signal transduction. It also strongly inhibits tumor growth and induces regression in subcutaneous xenograft models.

Irpagratinib (ABSK011) is a potent inhibitor of FGFR4 with an IC50 of < 10 nM in biochemical assays. It effectively suppresses FGFR4 auto-phosphorylation and disrupts downstream signal transduction. It also strongly inhibits tumor growth and induces regression in subcutaneous xenograft models.

Irpagratinib (ABSK011) is a potent inhibitor of FGFR4 with an IC50 of < 10 nM in biochemical assays. It effectively suppresses FGFR4 auto-phosphorylation and disrupts downstream signal transduction. It also strongly inhibits tumor growth and induces regression in subcutaneous xenograft models.